Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697 716. 11. Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006; 69: 406 411. 12. Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005; 45: 994 1001. 13. Wuhl E, Hadtstein C, Mehls O et al. Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure. Pediatr Res 2004; 55: 492 497. 14. Wuhl E, Trivelli A, Picca S et al. Strict blood-pressure control and progres- sion of renal failure in children. N Engl J Med 2009; 361: 1639 1650. 15. Powers BJ, Olsen MK, Smith VA et al. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med 2011; 154: 781 788, W-289 W-790. 16. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331 1340. 17. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93 104. 18. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovas- cular mortality in general population cohorts: a collaborative meta- analysis. Lancet 2010; 375: 2073 2081. 19. van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all- cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341 1352. 20. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17 28. 21. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903 1913. 22. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol 2010; 21: 1086 1092. 23. Ahmed AK, Kamath NS, El Kossi M et al. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3977 3982. 24. de Zeeuw D, Lambers-Heerspink H. Drug dosing for renoprotection: maybe it s time for a drug efficacy-safety score? J Am Soc Nephrol 2009; 20: 688 689. 25. Mason NA, Bailie GR, Satayathum S et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45: 119 126. 26. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395 1407. 27. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238 248. 28. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529 538. 29. Li Z, Lacson E, Jr., Lowrie EG et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: 606 615. 30. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S1 S179. 31. Acelajado MC, Oparil S. Hypertension in the elderly. Clin Geriatr Med 2009; 25: 391 412. 32. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Arterial stiffness in renal patients: an update. Am J Kidney Dis 2005; 45: 965 977. 33. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613 620. 34. Ohya Y, Iseki K, Iseki C et al. Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort. Am J Kidney Dis 2006; 47: 790 797. 35. Pannier B, Guerin AP, Marchais SJ et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005; 45: 592 596. 36. Toussaint ND, Lau KK, Strauss BJ et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 586 593. 37. Cockcroft JR, Wilkinson IB, Evans M et al. Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am J Hypertens 2005; 18: 1463 1467; discussion 1468 1469. 38. Domanski MJ, Davis BR, Pfeffer MA et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375 380. 39. Schram MT, Kostense PJ, Van Dijk RA et al. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 2002; 20: 1743 1751. 40. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884 893. 41. Somes GW, Pahor M, Shorr RI et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004 2009. 42. Denardo SJ, Gong Y, Nichols WW et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med 2010; 123: 719 726. 43. Oates DJ, Berlowitz DR, Glickman ME et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007; 55: 383 388. 44. Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens 2011; 24: 135 144. http://www.kidney-international.org references & 2012 KDIGO 45. Wu JS, Yang YC, Lu FH et al. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens Res 2008; 31: 897 904. 46. Alderman MH. Salt, blood pressure, and human health. Hypertension 2000; 36: 890 893. 47. Jones DW, Kim JS, Andrew ME et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994; 12: 1433 1437. 48. Whelton SP, Chin A, Xin X et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493 503. 49. Chen L, Davey Smith G, Harbord RM et al. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med 2008; 5: e52. 50. Brown CD, Higgins M, Donato KA et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8: 605 619. 51. The Obesity in Asia Collaboration. Is central obesity a better discriminator of the risk of hypertension than body mass index in ethnically diverse populations? J Hypertens 2008; 26: 169 177. 52. Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause- specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083 1096. 53. Dickinson HO, Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24: 215 233. 54. Navaneethan SD, Yehnert H, Moustarah F et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1565 1574. 55. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248 256 e245. 56. James WP, Caterson ID, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905 917. 57. Topol EJ, Bousser MG, Fox KA et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo- controlled trial. Lancet 2010; 376: 517 523. 58. Kalantar-Zadeh K, Abbott KC, Salahudeen AK et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543 554. 59. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238 2245. 60. Hoogeveen EK, Halbesma N, Rothman KJ et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7: 280 288. 61. World Health Organization. Prevention of Cardiovascular Disease: Guide- lines for Assessment and Management of Total Cardiovascular Risk. 2007. 62. Hooper L, Bartlett C, Davey Smith G et al. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002; 325: 628. 63. Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474 481. 64. Phillips CO, Kashani A, Ko DK et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930 1936. 65. Slagman MC, Waanders F, Hemmelder MH et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343: d4366. 66. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999 1007. 67. Ekinci EI, Clarke S, Thomas MC et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 2011; 34: 703 709. 68. Thomas MC, Moran J, Forsblom C et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 2011; 34: 861 866. 69. Chen JL, Lerner D, Ruthazer R et al. Association of physical activity with mortality in chronic kidney disease. J Nephrol 2008; 21: 243 252. 70. O Hare AM, Tawney K, Bacchetti P et al. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 2003; 41: 447 454. 71. Stack AG, Molony DA, Rives T et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45: 690 701. 72. World Health Organization. International Guide for Monitoring Alcohol Consumption and Related Harm. 2000. 73. Jee SH, Miller ER, 3rd, Guallar E et al. The effect of magnesium supplemen- tation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 2002; 15: 691 696. 74. Campbell F, Dickinson HO, Critchley JA et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol 2012 (in press). 75. Donadio JV, Jr., Bergstralh EJ, Offord KP et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194 1199. 76. Swan SK, Olyaei A, Sica D. Clinical pharmacology for the nephrologist. NephSap 2010; 9: 220 264. 77. Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am J Nephrol 2006; 26: 503 510. 78. Davidson MB, Hix JK, Vidt DG et al. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 2006; 166: 846 852. 79. Minutolo R, Agarwal R, Borrelli S et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 2011; 171: 1090 1098. 80. Hermida RC, Ayala DE, Mojon A et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27: 1629 1651. 81. Hermida RC, Ayala DE, Mojon A et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011; 58: 1165 1173. 82. Hermida RC, Ayala DE, Mojon A et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313 2321. 83. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399 407. 84. US Food and Drug Administration. Public health advisory: Angiotensin- converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. http:// www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ PublicHealthAdvisories/ucm053113.htm (accessed 2 July 2012). 85. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003; 16: 123 126. 86. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angio- tensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16 29. 87. Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282 287. 88. Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? Kidney Int 2011; 80: 235 237. 89. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486 492. 90. Palmer BF. Renal dysfunction complicating the treatment of hyperten- sion. N Engl J Med 2002; 347: 1256 1261. 91. Bridoux F, Hazzan M, Pallot JL et al. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7: 100 104. 92. Kohli HS, Bhaskaran MC, Muthukumar T et al. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant 2000; 15: 212 217. 93. Wynckel A, Ebikili B, Melin JP et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am J Hypertens 1998; 11: 1080 1086. 94. Adhiyaman V, Asghar M, Oke A et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001; 94: 512 514. 95. Loboz KK, Shenfield GM. Drug combinations and impaired renal function the triple whammy . Br J Clin Pharmacol 2005; 59: 239 243. 96. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin- converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244 252. 97. Balamuthusamy S, Srinivasan L, Verma M et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008; 155: 791 805. 98. Oregon Health Resources Commission. Direct Renin Inhibitors, Angioten- sin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers Draft. January 2010. references 99. Oregon Health Resources Commission. Angiotensin-Converting Enzyme Inhibitors (ACEIs) Subcommittee Report Update. July 2005. 100. Oregon Health Resources Commission. Angiotensin II Receptor Antago- nists (AIIRA) Subcommittee Report. March 2006. 101. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173 1181. 102. Batterink J, Stabler SN, Tejani AM et al. Spironolactone for hypertension. Cochrane Database Syst Rev 2010: CD008169. 103. Becker GJ, Hewitson TD, Chrysostomou A. Aldosterone in clinical nephrology old hormone, new questions. Nephrol Dial Transplant 2009; 24: 2316 2321. 104. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677 688. 105. Goodfriend TL. Treating resistant hypertension with a neglected old drug. Hypertension 2007; 49: 763 764. 106. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940 951. 107. Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199 211. 108. Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin- converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641 2650. 109. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116 2123. 110. Toto RD. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 2010; 19: 444 449. 111. Rebello S, Compain S, Feng A et al. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol 2011; 51: 1549 1560. 112. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433 2446. 113. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663 1671. 114. US Food and Drug Administration. FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). (http://www.fda.gov/Drugs/DrugSafety/ ucm300889.htm). 115. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361: 2153 2164. 116. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592 2597. 117. National Clinical Guideline Center. Hypertension. The Clinical Manage- ment of Primary Hypertension in Adults. Clinical Guideline 127. Commis- sioned by the National Institute for Health and Clinical Excellence, 2011. 118. Gallagher M, Perkovic V, Chalmers J. Diuretics: a modern day treatment option? Nephrology (Carlton) 2006; 11: 419 427. 119. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010; 8: 793 802. 120. Dussol B, Moussi-Frances J, Morange S et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349 353. 121. Musini VM, Wright JM, Bassett K et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2009: CD003825. 122. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 2009; 53: 379 387. 123. Frishman WH, Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002; 41: 505 516. 124. Ram CV. Beta-blockers in hypertension. Am J Cardiol 2010; 106: 1819 1825. 125. Oregon Health Resources Commission. Beta Adrenergic Blockers Pharma- ceutical Subcommittee Report. Update #3, March 2008. 126. Badve SV, Roberts MA, Hawley CM et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 1152 1161. 127. Chen JM, Heran BS, Perez MI et al. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev 2010: CD007185. 128. Ritz E, Rump LC. Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury? Curr Hypertens Rep 2007; 9: 409 414. 129. Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens 2003; 12: 123 131. 130. Bakris GL, Weir MR, Secic M et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991 2002. 131. Oregon Health Resources Commission. Calcium Channel Blocker Sub- committee Report Update #2. May 2005. 132. Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int 2008; 73: 795 796. 133. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs 2006; 66: 477 496. 134. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9: 399 405. 135. Vonend O, Marsalek P, Russ H et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709 1717. 136. Cohn JN, Pfeffer MA, Rouleau J et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659 667. 137. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659 663. 138. Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis 2005; 45: 223 232. 139. Upadhyay A, Earley A, Haynes SM et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154: 541 548. 140. Appel LJ, Wright JT, Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918 929. 141. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73 87. 142. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754 762. 143. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treat- ment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560 2572. 144. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291 1297. 145. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844 850. 146. Hsu CY, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342 350. 147. Hsu CY, McCulloch CE, Darbinian J et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923 928. 148. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13 18. 149. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887 1898. 150. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121 1123. 151. SHEP Cooperative Research Group. Prevention of stroke by antihyper- tensive drug treatment in older persons with isolated systolic hyperten- sion. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255 3264. 152. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296 1305. 153. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154 2169. references 154. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019 2032. 155. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085 2098. 156. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490 1494. 157. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommenda- tions for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058 2065. 158. Weiner DE, Tighiouart H, Levey AS et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007; 18: 960 966. 159. Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood- pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575 1585. 160. Pahor M, Shorr RI, Somes GW et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998; 158: 1340 1345. 161. National Institute for Health and Clinical Excellence. Chronic Kidney Disease: Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 73. 2008. 162. Hallan SI, Ritz E, Lydersen S et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069 1077. 163. Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423 429. 164. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777 1782. 165. Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901 906. 166. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342 351. 167. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hyperten- sion optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218 225. 168. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908 1919. 169. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877 884. 170. Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN- 2): multicentre, randomised controlled trial. Lancet 2005; 365: 939 946. 171. National Heart Lung and Blood Institute. NIH blood pressure trial expands into include more older adults. http://public.nhlbi.nih.gov/ newsroom/home/GetPressRelease.aspx?id=2737. 172. National Heart Lung and Blood Institute. NIH launches multicenter clinical trial to test blood pressure strategy. http://public.nhlbi.nih.gov/ newsroom/home/GetPressRelease.aspx?id=2667. 173. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629 636. 174. Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641 647. 175. Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hyper- tensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936 946. 176. Rahman M, Pressel S, Davis BR et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172 180. 177. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized con- trolled trial. JAMA 2001; 285: 2719 2728. 178. Saruta T, Hayashi K, Ogihara T et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. Hypertens Res 2009; 32: 505 512. 179. Mann JF, Schmieder RE, Dyal L et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1 10, W11 W12. 180. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577 1578. 181. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870 878. 182. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861 869. 183. Estacio RO, Jeffers BW, Gifford N et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54 B64. 184. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851 860. 185. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145 153. 186. Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardio- vascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18: 2766 2772. 187. Solomon SD, Rice MM, K AJ et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114: 26 31. 188. Solomon SD, Lin J, Solomon CG et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 2007; 116: 2687 2693. 189. Brugts JJ, Boersma E, Chonchol M et al. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007; 50: 2148 2155. 190. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809 2816. 191. Li PK, Leung CB, Chow KM et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751 760. 192. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131 140. 193. Heerspink HL, de Zeeuw D. Composite renal endpoints: was ACCOM- PLISH accomplished? Lancet 2010; 375: 1140 1142. 194. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52: 1036 1040. 195. Kramer HJ, Nguyen QD, Curhan G et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273 3277. 196. MacIsaac RJ, Panagiotopoulos S, McNeil KJ et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006; 29: 1560 1566. 197. Perkins BA, Ficociello LH, Roshan B et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010; 77: 57 64. 198. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665. 199. Czernichow S, Zanchetti A, Turnbull F et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta- analysis of randomized trials. J Hypertens 2011; 29: 4 16. 200. O Seaghdha CM, Perkovic V, Lam TH et al. Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region. Hypertension 2009; 54: 509 515. references 201. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12- yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434 444. 202. White SL, Chadban SJ, Jan S et al. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008; 86: 229 237. 203. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225 232. 204. Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006; 2: 562 567. 205. Janka HU, Warram JH, Rand LI et al. Risk factors for progression of back- ground retinopathy in long-standing IDDM. Diabetes 1989; 38: 460 464. 206. Klein R, Klein BE, Moss SE et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427 2432. 207. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retino- pathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 1980; 302: 645 650. 208. Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246 251. 209. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580 591. 210. Gaede P, Tarnow L, Vedel P et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784 2788. 211. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardio- vascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383 393. 212. An JH, Cho YM, Yu HG et al. The clinical characteristics of normoalbu- minuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. J Korean Med Sci 2009; 24 (Suppl): S75 S81. 213. Bruno G, Merletti F, Bargero G et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 2007; 50: 941 948. 214. Ito H, Takeuchi Y, Ishida H et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2010; 25: 1161 1167. 215. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27: 195 200. 216. Thomas MC, Macisaac RJ, Jerums G et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009; 32: 1497 1502. 217. Yokoyama H, Sone H, Oishi M et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009; 24: 1212 1219. 218. Molitch ME, Steffes M, Sun W et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33: 1536 1543. 219. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703 713. 220. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755 1762. 221. Schrier RW, Estacio RO, Mehler PS et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007; 3: 428 438. 222. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645 652. 223. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086 1097. 224. Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233 244. 225. Perry HM, Jr., Miller JP, Fornoff JR et al. Early predictors of 15-year end- stage renal disease in hypertensive patients. Hypertension 1995; 25: 587 594. 226. Tozawa M, Iseki K, Iseki C et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341 1345. 227. Orchard TJ, Forrest KY, Kuller LH et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001; 24: 1053 1059. 228. Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170 2179. 229. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412 419. 230. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil- Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805 2816. 231. Cooper-DeHoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61 68. 232. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular out- comes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829 840. 233. de Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883 892. 234. Heerspink HJ, Ninomiya T, Perkovic V et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010; 31: 2888 2896. 235. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25: 134 147. 236. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011 1053. 237. Australian Heart Foundation. Guide to Management of Hypertension. 2008. 238. Levin A, Hemmelgarn B, Culleton B et al. Guidelines for the management of chronic kidney disease. CMAJ 2008; 179: 1154 1162. 239. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462 1536. 240. Joint British Societies 2 Working Party. JBS 2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5): v1 v52. 241. World Health Organization-International Society of Hypertension (WHO- ISH) Guidelines Subcommittee. 1999 World Health Organization-Interna- tional Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151 183. 242. JNC VI. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413 2446. 243. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983 1992. 244. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hyperten- sion Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139 185. 245. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26 (Suppl 1): S80 S82. 246. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care 2010; 33 (Suppl 1): S11 S61. 247. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114 126. references 248. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757 764. 249. Nishimura R, LaPorte RE, Dorman JS et al. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965 1999. Diabetes Care 2001; 24: 823 827. 250. Ibsen H, Olsen MH, Wachtell K et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595 600. 251. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941 1951. 252. Ruggenenti P, Perna A, Ganeva M et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472 3481. 253. Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617 622. 254. Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555 1565. 255. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646 661. 256. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413 1418. 257. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421 426. 258. Ninomiya T, Perkovic V, de Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813 1821. 259. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281 287. 260. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309 2320. 261. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921 927. 262. Agha A, Amer W, Anwar E et al. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial. Saudi J Kidney Dis Transpl 2009; 20: 429 435. 263. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin- converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370 379. 264. Marre M, Lievre M, Chatellier G et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328: 495. 265. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent dia- betes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286 289. 266. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577 581. 267. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8: 876 883. 268. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 update. Am J Kidney Dis 2012; 60: 850 886. 269. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collabora- tive Study Group. N Engl J Med 1993; 329: 1456 1462. 270. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129 138. 271. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting- enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058 2068. 272. Dagenais GR, Pogue J, Fox K et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581 588. 273. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995 1003. 274. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double- blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782 788. 275. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033 1041. 276. Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174 1183. 277. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO- HOPE substudy. Heart Outcomes Prevention Evaluation Study Investi- gators. Lancet 2000; 355: 253 259. 278. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004 1010. 279. Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Low- ering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401 1409. 280. Strippoli GF, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828. 281. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547 553. 282. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547 1559. 283. Chrysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256 262. 284. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648 654. 285. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18: 596 604. 286. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66: 441 447. 287. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735 1743. 288. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603 611. 289. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217 222. 290. Opelz G, Dohler B. Improved long-term outcomes after renal transplan- tation associated with blood pressure control. Am J Transplant 2005; 5: 2725 2731. 291. Kasiske BL, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071 1081. 292. KDIGO Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1 S155. references 293. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hyper- tension. Nephrol Dial Transplant 2002; 17 (Suppl 4): 25 26. 294. Gaston RS, Kasiske BL, Fieberg AM et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811 1815. 295. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024 2031. 296. Gill JS. Cardiovascular disease in transplant recipients: current and future treatment strategies. Clin J Am Soc Nephrol 2008; 3 (Suppl 2): S29 S37. 297. Kuypers DR, Neumayer HH, Fritsche L et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78: 1204 1211. 298. Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787 1792. 299. Rahn KH, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354: 1415 1420. 300. van Riemsdijk IC, Mulder PG, de Fijter JW et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Trans- plantation 2000; 70: 122 126. 301. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of rando- mized controlled trials. Transplantation 2009; 88: 7 18. 302. Knoll GA, Blydt-Hansen TD, Campbell P et al. Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 2010; 56: 219 246. 303. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosup- pressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384 389. 304. Dawson KL, Patel SJ, Putney D et al. Cardioprotective medication use after renal transplantation. Clin Transplant 2010; 24: E253 E256. 305. Hiremath S, Fergusson D, Doucette S et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350 2360. 306. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889 899. 307. Opelz G, Zeier M, Laux G et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257 3262. 308. el-Agroudy AE, Hassan NA, Foda MA et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300 306. 309. Philipp T, Martinez F, Geiger H et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25: 967 976. 310. Knoll GA, Cantarovitch M, Cole E et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 2008; 23: 354 358. 311. Ardissino G, Vigano S, Testa S et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplas- tic nephropathy report from the ItalKid Project database. Nephrol Dial Transplant 2007; 22: 2525 2530. 312. Flynn JT, Mitsnefes M, Pierce C et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52: 631 637. 313. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003; 14: 2618 2622. 314. Sinha R, Saad A, Marks SD. Prevalence and complications of chronic kidney disease in paediatric renal transplantation: a K/DOQI perspective. Nephrol Dial Transplant 2010; 25: 1313 1320. 315. Wong H, Mylrea K, Feber J et al. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 2006; 70: 585 590. 316. Chavers BM, Li S, Collins AJ et al. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 2002; 62: 648 653. 317. Parekh RS, Carroll CE, Wolfe RA et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002; 141: 191 197. 318. Lilien MR, Groothoff JW. Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol 2009; 5: 229 235. 319. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555 576. 320. Dionne JM, Turik MM, Hurley RM. Blood pressure abnormalities in children with chronic kidney disease. Blood Press Monit 2008; 13: 205 209. 321. Gimpel C, Wuhl E, Arbeiter K et al. Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials. J Hypertens 2009; 27: 1568 1574. 322. Krmar RT, Berg UB. Blood pressure control in hypertensive pediatric renal transplants: role of repeated ABPM following transplantation. Am J Hypertens 2008; 21: 1093 1099. 323. Wuhl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004; 66: 768 776. 324. Groothoff JW, Lilien MR, van de Kar NC et al. Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 2005; 20: 374 379. 325. Mitsnefes M, Flynn J, Cohn S et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21: 137 144. 326. Sorof JM, Alexandrov AV, Cardwell G et al. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 2003; 111: 61 66. 327. Muntner P, Arshad A, Morse SA et al. End-stage renal disease in young black males in a black-white population: longitudinal analysis of the Bogalusa Heart Study. BMC Nephrol 2009; 10: 40. 328. Li S, Chen W, Srinivasan SR et al. Childhood blood pressure as a predictor of arterial stiffness in young adults: the bogalusa heart study. Hypertension 2004; 43: 541 546. 329. Juonala M, Jarvisalo MJ, Maki-Torkko N et al. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: the Cardio- vascular Risk in Young Finns Study. Circulation 2005; 112: 1486 1493. 330. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high- risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114: 2710 2738. 331. Gonzalez Celedon C, Bitsori M, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol 2007; 22: 1014 1020. 332. Wingen AM, Fabian-Bach C, Schaefer F et al. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349: 1117 1123. 333. Silverstein DM, Leblanc P, Hempe JM et al. Tracking of blood pressure and its impact on graft function in pediatric renal transplant patients. Pediatr Transplant 2007; 11: 860 867. 334. Mitsnefes MM, Omoloja A, McEnery PT. Short-term pediatric renal transplant survival: blood pressure and allograft function. Pediatr Transplant 2001; 5: 160 165. 335. Seeman T, Pohl M, Misselwitz J et al. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. Kidney Blood Press Res 2009; 32: 440 444. 336. Furth SL, Flynn JT, Pierce CB et al. Lower systolic BP associated with slower CKD progression in the CKiD study. J Am Soc Nephrol 2010; 21: 551A. 337. Lurbe E, Cifkova R, Cruickshank JK et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009; 27: 1719 1742. references 338. Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child 2011; 96: 881 882. 339. Simonetti GD, Santoro L, Ferrarini A et al. Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management. Paediatr Drugs 2007; 9: 413 418. 340. Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol 2008; 23: 363 371. 341. Hogg RJ, Delucchi A, Sakihara G et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 2007; 22: 695 701. 342. Li D, Xing H, Hao K et al. Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study. Ann Epidemiol 2004; 14: 123 128. 343. Soffer B, Zhang Z, Miller K et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003; 16: 795 800. 344. Wells T, Frame V, Soffer B et al. 